nach oben

European Journal of Nutrition

Erschienen in:

02.03.2021 | Review

Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes

verfasst von: Yasaman Ghorbani, Katherine J. P. Schwenger, Johane P. Allard

Erschienen in: European Journal of Nutrition | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Increasing evidence suggests that the intestinal microbiome (IM) and bacterial metabolites may influence glucose homeostasis, energy expenditure and the intestinal barrier integrity and lead to the presence of systemic low-grade inflammation, all of which can contribute to insulin resistance (IR) and type 2 diabetes (T2D). The purpose of this review is to explore the role of the IM and bacterial metabolites in the pathogenesis and treatment of these conditions.

Results

This review summarizes research focused on how to modulate the IM through diet, prebiotics, probiotics, synbiotics and fecal microbiota transplant in order to treat IR and T2D.

Conclusion

There is an abundance of evidence suggesting a role for IM in the pathogenesis of IR and T2D based on reviewed studies using various methods to modulate IM and metabolites. However, the results are inconsistent. Future research should further assess this relationship.

Organization WH (2018) The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 19 August 2020

Organization WH (2016) Global report on diabetes. https://www.who.int/publications/i/item/9789241565257

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R, Committee IDFDA (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843CrossRefPubMed

Pulgaron ER, Delamater AM (2014) Obesity and type 2 diabetes in children: epidemiology and treatment. Curr Diab Rep 14(8):508. https://doi.org/10.1007/s11892-014-0508-yCrossRefPubMedPubMedCentral

Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG (2006) Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care 29(11):2427–2432. https://doi.org/10.2337/dc06-0709CrossRefPubMed

Freeman AM, Pennings N (2020) Insulin Resistance. StatPearls, Treasure Island (FL)

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE (2017) Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66(2):241–255. https://doi.org/10.2337/db16-0806CrossRefPubMed

Sun X, Yu W, Hu C (2014) Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. Biomed Res Int 2014:926713. https://doi.org/10.1155/2014/926713CrossRefPubMedPubMedCentral

Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proenca C, Bacot F, Balkau B, Belisle A, Borch-Johnsen K, Charpentier G, Dina C, Durand E, Elliott P, Hadjadj S, Jarvelin MR, Laitinen J, Lauritzen T, Marre M, Mazur A, Meyre D, Montpetit A, Pisinger C, Posner B, Poulsen P, Pouta A, Prentki M, Ribel-Madsen R, Ruokonen A, Sandbaek A, Serre D, Tichet J, Vaxillaire M, Wojtaszewski JF, Vaag A, Hansen T, Polychronakos C, Pedersen O, Froguel P, Sladek R (2009) Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 41(10):1110–1115. https://doi.org/10.1038/ng.443CrossRefPubMed

10.

Marin-Penalver JJ, Martin-Timon I, Sevillano-Collantes C, Del Canizo-Gomez FJ (2016) Update on the treatment of type 2 diabetes mellitus. World J Diabetes 7(17):354–395. https://doi.org/10.4239/wjd.v7.i17.354CrossRefPubMedPubMedCentral

11.

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR, Investigators S (2017) Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 376(7):641–651. https://doi.org/10.1056/NEJMoa1600869CrossRefPubMedPubMedCentral

12.

Caricilli AM, Saad MJ (2013) The role of gut microbiota on insulin resistance. Nutrients 5(3):829–851. https://doi.org/10.3390/nu5030829CrossRefPubMedPubMedCentral

13.

Wilcox G (2005) Insulin and insulin resistance. Clin Biochem Rev 26(2):19–39PubMedPubMedCentral

14.

Smith U (2002) Impaired ('diabetic’) insulin signaling and action occur in fat cells long before glucose intolerance–is insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord 26(7):897–904. https://doi.org/10.1038/sj.ijo.0802028CrossRefPubMed

15.

Hunter SJ, Garvey WT (1998) Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 105(4):331–345. https://doi.org/10.1016/s0002-9343(98)00300-3CrossRefPubMed

16.

Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27(6):1487–1495. https://doi.org/10.2337/diacare.27.6.1487CrossRefPubMed

17.

Sumner AE, Cowie CC (2008) Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 196(2):696–703. https://doi.org/10.1016/j.atherosclerosis.2006.12.018CrossRefPubMed

18.

Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Garcia F, De Francisco A, Quintela AG (2013) Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 13:47. https://doi.org/10.1186/1472-6823-13-47CrossRefPubMedPubMedCentral

19.

Cantley J, Ashcroft FM (2015) Q&A: insulin secretion and type 2 diabetes: why do beta-cells fail? BMC Biol 13:33. https://doi.org/10.1186/s12915-015-0140-6CrossRefPubMedPubMedCentral

20.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi P, Wheeler DC, Group ESCSD (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486CrossRefPubMed

21.

American Diabetes A (2019) 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 42(Suppl 1):S13–S28. https://doi.org/10.2337/dc19-S002CrossRef

22.

Dedoussis GV, Kaliora AC, Panagiotakos DB (2007) Genes, diet and type 2 diabetes mellitus: a review. Rev Diabet Stud 4(1):13–24. https://doi.org/10.1900/RDS.2007.4.13CrossRefPubMedPubMedCentral

23.

Belkina AC, Denis GV (2010) Obesity genes and insulin resistance. Curr Opin Endocrinol Diabetes Obes 17(5):472–477. https://doi.org/10.1097/MED.0b013e32833c5c48CrossRefPubMedPubMedCentral

24.

Wu H, Ballantyne CM (2020) Metabolic inflammation and insulin resistance in obesity. Circ Res 126(11):1549–1564. https://doi.org/10.1161/CIRCRESAHA.119.315896CrossRefPubMedPubMedCentral

25.

Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444(7121):840–846. https://doi.org/10.1038/nature05482CrossRefPubMed

26.

Statovci D, Aguilera M, MacSharry J, Melgar S (2017) The impact of western diet and nutrients on the microbiota and immune response at mucosal interfaces. Front Immunol 8:838. https://doi.org/10.3389/fimmu.2017.00838CrossRefPubMedPubMedCentral

27.

Rosenheck R (2008) Fast food consumption and increased caloric intake: a systematic review of a trajectory towards weight gain and obesity risk. Obes Rev 9(6):535–547. https://doi.org/10.1111/j.1467-789X.2008.00477.xCrossRefPubMed

28.

Brons C, Jensen CB, Storgaard H, Hiscock NJ, White A, Appel JS, Jacobsen S, Nilsson E, Larsen CM, Astrup A, Quistorff B, Vaag A (2009) Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men. J Physiol 587(Pt 10):2387–2397. https://doi.org/10.1113/jphysiol.2009.169078CrossRefPubMedPubMedCentral

29.

Bisschop PH, de Metz J, Ackermans MT, Endert E, Pijl H, Kuipers F, Meijer AJ, Sauerwein HP, Romijn JA (2001) Dietary fat content alters insulin-mediated glucose metabolism in healthy men. Am J Clin Nutr 73(3):554–559. https://doi.org/10.1093/ajcn/73.3.554CrossRefPubMed

30.

Montell E, Turini M, Marotta M, Roberts M, Noe V, Ciudad CJ, Mace K, Gomez-Foix AM (2001) DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am J Physiol Endocrinol Metab 280(2):E229-237. https://doi.org/10.1152/ajpendo.2001.280.2.E229CrossRefPubMed

31.

Finck BN, Hall AM (2015) Does diacylglycerol accumulation in fatty liver disease cause hepatic insulin resistance? Biomed Res Int 2015:104132. https://doi.org/10.1155/2015/104132CrossRefPubMedPubMedCentral

32.

Ertunc ME, Hotamisligil GS (2016) Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res 57(12):2099–2114. https://doi.org/10.1194/jlr.R066514CrossRefPubMedPubMedCentral

33.

Kolczynska K, Loza-Valdes A, Hawro I, Sumara G (2020) Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review. Lipids Health Dis 19(1):113. https://doi.org/10.1186/s12944-020-01286-8CrossRefPubMedPubMedCentral

34.

Ghemrawi R, Battaglia-Hsu SF, Arnold C (2018) Endoplasmic reticulum stress in metabolic disorders. Cells. https://doi.org/10.3390/cells7060063CrossRefPubMedPubMedCentral

35.

Ho N, Xu C, Thibault G (2018) From the unfolded protein response to metabolic diseases: lipids under the spotlight. J Cell Sci. https://doi.org/10.1242/jcs.199307CrossRefPubMedPubMedCentral

36.

Oh YS, Bae GD, Baek DJ, Park EY, Jun HS (2018) Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol (Lausanne) 9:384. https://doi.org/10.3389/fendo.2018.00384CrossRef

37.

Yi X, Cai X, Wang S, Xiao Y (2020) Mechanisms of impaired pancreatic betacell function in highfat dietinduced obese mice: the role of endoplasmic reticulum stress. Mol Med Rep 21(5):2041–2050. https://doi.org/10.3892/mmr.2020.11013CrossRefPubMedPubMedCentral

38.

Preston AM, Gurisik E, Bartley C, Laybutt DR, Biden TJ (2009) Reduced endoplasmic reticulum (ER)-to-Golgi protein trafficking contributes to ER stress in lipotoxic mouse beta cells by promoting protein overload. Diabetologia 52(11):2369–2373. https://doi.org/10.1007/s00125-009-1506-5CrossRefPubMed

39.

Beigrezaei S, Ghiasvand R, Feizi A, Iraj B (2019) Relationship between dietary patterns and incidence of type 2 diabetes. Int J Prev Med 10:122. https://doi.org/10.4103/ijpvm.IJPVM_206_17CrossRefPubMedPubMedCentral

40.

Cnop M, Abdulkarim B, Bottu G, Cunha DA, Igoillo-Esteve M, Masini M, Turatsinze JV, Griebel T, Villate O, Santin I, Bugliani M, Ladriere L, Marselli L, McCarthy MI, Marchetti P, Sammeth M, Eizirik DL (2014) RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. Diabetes 63(6):1978–1993. https://doi.org/10.2337/db13-1383CrossRefPubMed

41.

Brown AE, Walker M (2016) Genetics of insulin resistance and the metabolic syndrome. Curr Cardiol Rep 18(8):75. https://doi.org/10.1007/s11886-016-0755-4CrossRefPubMedPubMedCentral

42.

Repaske DR (2016) Medication-induced diabetes mellitus. Pediatr Diabetes 17(6):392–397. https://doi.org/10.1111/pedi.12406CrossRefPubMed

43.

Mi D, Fang H, Zhao Y, Zhong L (2017) Birth weight and type 2 diabetes: a meta-analysis. Exp Ther Med 14(6):5313–5320. https://doi.org/10.3892/etm.2017.5234CrossRefPubMedPubMedCentral

44.

Schippa S, Conte MP (2014) Dysbiotic events in gut microbiota: impact on human health. Nutrients 6(12):5786–5805. https://doi.org/10.3390/nu6125786CrossRefPubMedPubMedCentral

45.

Deng F, Li Y, Zhao J (2019) The gut microbiome of healthy long-living people. Aging (Albany NY) 11(2):289–290. https://doi.org/10.18632/aging.101771CrossRef

46.

Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jorgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clement K, Dore J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Meta HITc, Bork P, Wang J, Ehrlich SD, Pedersen O (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464):541–546. https://doi.org/10.1038/nature12506CrossRefPubMed

47.

Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L (2016) Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep 6:32002. https://doi.org/10.1038/srep32002CrossRefPubMedPubMedCentral

48.

Gong D, Gong X, Wang L, Yu X, Dong Q (2016) Involvement of reduced microbial diversity in inflammatory bowel disease. Gastroenterol Res Pract 2016:6951091. https://doi.org/10.1155/2016/6951091CrossRefPubMedPubMedCentral

49.

Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K, Vermeire S, Sokol H, Guarner F, Manichanh C (2017) A microbial signature for Crohn’s disease. Gut 66(5):813–822. https://doi.org/10.1136/gutjnl-2016-313235CrossRefPubMed

50.

Mosca A, Leclerc M, Hugot JP (2016) Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol 7:455. https://doi.org/10.3389/fmicb.2016.00455CrossRefPubMedPubMedCentral

51.

Li Q, Chang Y, Zhang K, Chen H, Tao S, Zhang Z (2020) Implication of the gut microbiome composition of type 2 diabetic patients from northern China. Sci Rep 10(1):5450. https://doi.org/10.1038/s41598-020-62224-3CrossRefPubMedPubMedCentral

52.

Doumatey AP, Adeyemo A, Zhou J, Lei L, Adebamowo SN, Adebamowo C, Rotimi CN (2020) Gut microbiome profiles are associated with type 2 diabetes in urban africans. Front Cell Infect Microbiol 10:63. https://doi.org/10.3389/fcimb.2020.00063CrossRefPubMedPubMedCentral

53.

Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C (2018) Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 24(12):1919–1929. https://doi.org/10.1038/s41591-018-0222-4CrossRefPubMedPubMedCentral

54.

Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sorensen SJ, Hansen LH, Jakobsen M (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5(2):e9085. https://doi.org/10.1371/journal.pone.0009085CrossRefPubMedPubMedCentral

55.

Gaike AH, Paul D, Bhute S, Dhotre DP, Pande P, Upadhyaya S, Reddy Y, Sampath R, Ghosh D, Chandraprabha D, Acharya J, Banerjee G, Sinkar VP, Ghaskadbi SS, Shouche YS (2020) The gut microbial diversity of newly diagnosed diabetics but not of prediabetics is significantly different from that of healthy nondiabetics. mSystems. https://doi.org/10.1128/mSystems.00578-19CrossRefPubMedPubMedCentral

56.

Ahmad A, Yang W, Chen G, Shafiq M, Javed S, Ali Zaidi SS, Shahid R, Liu C, Bokhari H (2019) Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals. PLoS ONE 14(12):e0226372. https://doi.org/10.1371/journal.pone.0226372CrossRefPubMedPubMedCentral

57.

Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 8(8):e71108. https://doi.org/10.1371/journal.pone.0071108CrossRefPubMedPubMedCentral

58.

Tilg H, Kaser A (2011) Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 121(6):2126–2132. https://doi.org/10.1172/JCI58109CrossRefPubMedPubMedCentral

59.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490(7418):55–60. https://doi.org/10.1038/nature11450CrossRefPubMed

60.

Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, Shulzhenko N (2020) Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51:102590. https://doi.org/10.1016/j.ebiom.2019.11.051CrossRefPubMedPubMedCentral

61.

Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, Hallen A, Martens E, Bjorck I, Backhed F (2015) Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab 22(6):971–982. https://doi.org/10.1016/j.cmet.2015.10.001CrossRefPubMed

62.

Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmiri F, Mehrtash A, Amirmozafari N (2017) Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog 111:362–369. https://doi.org/10.1016/j.micpath.2017.08.038CrossRefPubMed

63.

Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, Yu P, Zhao C, Li L, Zhou A, Wang J, Moore JE, Millar BC, Xu J (2010) Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61(1):69–78. https://doi.org/10.1007/s00284-010-9582-9CrossRefPubMed

64.

Gao R, Zhu C, Li H, Yin M, Pan C, Huang L, Kong C, Wang X, Zhang Y, Qu S, Qin H (2018) Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with overweight and obesity. Obesity (Silver Spring) 26(2):351–361. https://doi.org/10.1002/oby.22088CrossRef

65.

Sasaki M, Ogasawara N, Funaki Y, Mizuno M, Iida A, Goto C, Koikeda S, Kasugai K, Joh T (2013) Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study. BMC Gastroenterol 13:81. https://doi.org/10.1186/1471-230X-13-81CrossRefPubMedPubMedCentral

66.

Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498(7452):99–103. https://doi.org/10.1038/nature12198CrossRefPubMed

67.

Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR (2013) Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 13(6):514–522. https://doi.org/10.1038/tpj.2012.43CrossRefPubMed

68.

Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jorgensen T, Levenez F, Dore J, Meta HITc, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528(7581):262–266. https://doi.org/10.1038/nature15766CrossRefPubMedPubMedCentral

69.

Aydin O, Nieuwdorp M, Gerdes V (2018) The gut microbiome as a target for the treatment of type 2 diabetes. Curr Diab Rep 18(8):55. https://doi.org/10.1007/s11892-018-1020-6CrossRefPubMedPubMedCentral

70.

Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4):913-916 e917. https://doi.org/10.1053/j.gastro.2012.06.031CrossRefPubMed

71.

Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozinska S, Ludwig-Slomczynska AH, Wolkow PP, Bulanda M, Klupa T, Malecki MT, Gosiewski T (2018) Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on nextgeneration sequencing of the 16S rRNA gene fragment. Pol Arch Intern Med 128(6):336–343. https://doi.org/10.20452/pamw.4246CrossRefPubMed

72.

Remely M, Aumueller E, Merold C, Dworzak S, Hippe B, Zanner J, Pointner A, Brath H, Haslberger AG (2014) Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene 537(1):85–92. https://doi.org/10.1016/j.gene.2013.11.081CrossRefPubMed

73.

Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J, Henegar C, Rizkalla S, Clement K (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59(12):3049–3057. https://doi.org/10.2337/db10-0253CrossRefPubMedPubMedCentral

74.

Hermes GDA, Reijnders D, Kootte RS, Goossens GH, Smidt H, Nieuwdorp M, Blaak EE, Zoetendal EG (2020) Individual and cohort-specific gut microbiota patterns associated with tissue-specific insulin sensitivity in overweight and obese males. Sci Rep 10(1):7523. https://doi.org/10.1038/s41598-020-64574-4CrossRefPubMedPubMedCentral

75.

Greer RL, Dong X, Moraes AC, Zielke RA, Fernandes GR, Peremyslova E, Vasquez-Perez S, Schoenborn AA, Gomes EP, Pereira AC, Ferreira SR, Yao M, Fuss IJ, Strober W, Sikora AE, Taylor GA, Gulati AS, Morgun A, Shulzhenko N (2016) Akkermansia muciniphila mediates negative effects of IFNgamma on glucose metabolism. Nat Commun 7:13329. https://doi.org/10.1038/ncomms13329CrossRefPubMedPubMedCentral

76.

Allin KH, Tremaroli V, Caesar R, Jensen BAH, Damgaard MTF, Bahl MI, Licht TR, Hansen TH, Nielsen T, Dantoft TM, Linneberg A, Jorgensen T, Vestergaard H, Kristiansen K, Franks PW, Hansen T, Backhed F, Pedersen O, consortium I-D (2018) Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 61(4):810–820. https://doi.org/10.1007/s00125-018-4550-1CrossRefPubMedPubMedCentral

77.

Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 110(22):9066–9071. https://doi.org/10.1073/pnas.1219451110CrossRefPubMedPubMedCentral

78.

de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velasquez-Mejia EP, Carmona JA, Abad JM, Escobar JS (2017) Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40(1):54–62. https://doi.org/10.2337/dc16-1324CrossRefPubMed

79.

Larsen JM (2017) The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 151(4):363–374. https://doi.org/10.1111/imm.12760CrossRefPubMedPubMedCentral

80.

Iljazovic A, Roy U, Galvez EJC, Lesker TR, Zhao B, Gronow A, Amend L, Will SE, Hofmann JD, Pils MC, Schmidt-Hohagen K, Neumann-Schaal M, Strowig T (2021) Perturbation of the gut microbiome by Prevotella spp. enhances host susceptibility to mucosal inflammation. Mucosal Immunol 14(1):113–124. https://doi.org/10.1038/s41385-020-0296-4CrossRefPubMed

81.

Hippe B, Remely M, Aumueller E, Pointner A, Magnet U, Haslberger AG (2016) Faecalibacterium prausnitzii phylotypes in type two diabetic, obese, and lean control subjects. Benef Microbes 7(4):511–517. https://doi.org/10.3920/BM2015.0075CrossRefPubMed

82.

Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD (2017) A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23(1):107–113. https://doi.org/10.1038/nm.4236CrossRefPubMed

83.

Kang JH, Yun SI, Park MH, Park JH, Jeong SY, Park HO (2013) Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS ONE 8(1):e54617. https://doi.org/10.1371/journal.pone.0054617CrossRefPubMedPubMedCentral

84.

Li X, Wang N, Yin B, Fang D, Jiang T, Fang S, Zhao J, Zhang H, Wang G, Chen W (2016) Effects of Lactobacillus plantarum CCFM0236 on hyperglycaemia and insulin resistance in high-fat and streptozotocin-induced type 2 diabetic mice. J Appl Microbiol 121(6):1727–1736. https://doi.org/10.1111/jam.13276CrossRefPubMed

85.

Chen P, Zhang Q, Dang H, Liu X, Tian F, Zhao J, Chen Y, Zhang H, Chen W (2014) Antidiabetic effect of Lactobacillus casei CCFM0412 on mice with type 2 diabetes induced by a high-fat diet and streptozotocin. Nutrition 30(9):1061–1068. https://doi.org/10.1016/j.nut.2014.03.022CrossRefPubMed

86.

Wang G, Li X, Zhao J, Zhang H, Chen W (2017) Lactobacillus casei CCFM419 attenuates type 2 diabetes via a gut microbiota dependent mechanism. Food Funct 8(9):3155–3164. https://doi.org/10.1039/c7fo00593hCrossRefPubMed

87.

Tian P, Li B, He C, Song W, Hou A, Tian S, Meng X, Li K, Shan Y (2016) Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota. Food Funct 7(9):3789–3797. https://doi.org/10.1039/c6fo00831cCrossRefPubMed

88.

Zhang L, Qin Q, Liu M, Zhang X, He F, Wang G (2018) Akkermansia muciniphila can reduce the damage of gluco/lipotoxicity, oxidative stress and inflammation, and normalize intestine microbiota in streptozotocin-induced diabetic rats. Pathog Dis. https://doi.org/10.1093/femspd/fty028CrossRefPubMed

89.

Yang JY, Lee YS, Kim Y, Lee SH, Ryu S, Fukuda S, Hase K, Yang CS, Lim HS, Kim MS, Kim HM, Ahn SH, Kwon BE, Ko HJ, Kweon MN (2017) Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. Mucosal Immunol 10(1):104–116. https://doi.org/10.1038/mi.2016.42CrossRefPubMed

90.

Dang F, Jiang Y, Pan R, Zhou Y, Wu S, Wang R, Zhuang K, Zhang W, Li T, Man C (2018) Administration of Lactobacillus paracasei ameliorates type 2 diabetes in mice. Food Funct 9(7):3630–3639. https://doi.org/10.1039/c8fo00081fCrossRefPubMed

91.

Rooks MG, Garrett WS (2016) Gut microbiota, metabolites and host immunity. Nat Rev Immunol 16(6):341–352. https://doi.org/10.1038/nri.2016.42CrossRefPubMedPubMedCentral

92.

Alexander C, Swanson KS, Fahey GC, Garleb KA (2019) Perspective: physiologic importance of short-chain fatty acids from nondigestible carbohydrate fermentation. Adv Nutr 10(4):576–589. https://doi.org/10.1093/advances/nmz004CrossRefPubMedPubMedCentral

93.

Gerard C, Vidal H (2019) Impact of gut microbiota on host glycemic control. Front Endocrinol (Lausanne) 10:29. https://doi.org/10.3389/fendo.2019.00029CrossRef

94.

Chambers ES, Morrison DJ, Frost G (2015) Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? Proc Nutr Soc 74(3):328–336. https://doi.org/10.1017/S0029665114001657CrossRefPubMed

95.

Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, Anastasovska J, Ghourab S, Hankir M, Zhang S, Carling D, Swann JR, Gibson G, Viardot A, Morrison D, Louise Thomas E, Bell JD (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 5:3611. https://doi.org/10.1038/ncomms4611CrossRefPubMed

96.

Canfora EE, Jocken JW, Blaak EE (2015) Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 11(10):577–591. https://doi.org/10.1038/nrendo.2015.128CrossRefPubMed

97.

Silva YP, Bernardi A, Frozza RL (2020) The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne) 11:25. https://doi.org/10.3389/fendo.2020.00025CrossRef

98.

Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61(2):364–371. https://doi.org/10.2337/db11-1019CrossRefPubMedPubMedCentral

99.

Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418(6898):650–654. https://doi.org/10.1038/nature00887CrossRefPubMed

100.

Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86(9):4382–4389. https://doi.org/10.1210/jcem.86.9.7877CrossRefPubMed

101.

Nadkarni P, Chepurny OG, Holz GG (2014) Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci 121:23–65. https://doi.org/10.1016/B978-0-12-800101-1.00002-8CrossRefPubMedPubMedCentral

102.

Puddu A, Sanguineti R, Montecucco F, Viviani GL (2014) Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediat Inflamm 2014:162021. https://doi.org/10.1155/2014/162021CrossRef

103.

Roelofsen H, Priebe MG, Vonk RJ (2010) The interaction of short-chain fatty acids with adipose tissue: relevance for prevention of type 2 diabetes. Benef Microbes 1(4):433–437. https://doi.org/10.3920/BM2010.0028CrossRefPubMed

104.

Ma N, Wu Y, Xie F, Du K, Wang Y, Shi L, Ji L, Liu T, Ma X (2017) Dimethyl fumarate reduces the risk of mycotoxins via improving intestinal barrier and microbiota. Oncotarget 8(27):44625–44638. https://doi.org/10.18632/oncotarget.17886CrossRefPubMedPubMedCentral

105.

Zheng L, Kelly CJ, Battista KD, Schaefer R, Lanis JM, Alexeev EE, Wang RX, Onyiah JC, Kominsky DJ, Colgan SP (2017) Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J Immunol 199(8):2976–2984. https://doi.org/10.4049/jimmunol.1700105CrossRefPubMed

106.

Ploger S, Stumpff F, Penner GB, Schulzke JD, Gabel G, Martens H, Shen Z, Gunzel D, Aschenbach JR (2012) Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann NY Acad Sci 1258:52–59. https://doi.org/10.1111/j.1749-6632.2012.06553.xCrossRefPubMed

107.

Wang HB, Wang PY, Wang X, Wan YL, Liu YC (2012) Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci 57(12):3126–3135. https://doi.org/10.1007/s10620-012-2259-4CrossRefPubMed

108.

Liu H, Wang J, He T, Becker S, Zhang G, Li D, Ma X (2018) Butyrate: A double-edged sword for health? Adv Nutr 9(1):21–29. https://doi.org/10.1093/advances/nmx009CrossRefPubMedPubMedCentral

109.

Ma X, Fan PX, Li LS, Qiao SY, Zhang GL, Li DF (2012) Butyrate promotes the recovering of intestinal wound healing through its positive effect on the tight junctions. J Anim Sci 90(Suppl 4):266–268. https://doi.org/10.2527/jas.50965CrossRefPubMed

110.

Yan H, Ajuwon KM (2017) Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway. PLoS ONE 12(6):e0179586. https://doi.org/10.1371/journal.pone.0179586CrossRefPubMedPubMedCentral

111.

Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM (2010) Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 16(7):1138–1148. https://doi.org/10.1002/ibd.21177CrossRefPubMed

112.

Harsch IA, Konturek PC (2018) The role of gut microbiota in obesity and type 2 and type 1 diabetes mellitus: new insights into “Old” diseases. Med Sci (Basel). https://doi.org/10.3390/medsci6020032CrossRef

113.

Sakai J, Cammarota E, Wright JA, Cicuta P, Gottschalk RA, Li N, Fraser IDC, Bryant CE (2017) Lipopolysaccharide-induced NF-kappaB nuclear translocation is primarily dependent on MyD88, but TNFalpha expression requires TRIF and MyD88. Sci Rep 7(1):1428. https://doi.org/10.1038/s41598-017-01600-yCrossRefPubMedPubMedCentral

114.

Backhed F, Normark S, Schweda EK, Oscarson S, Richter-Dahlfors A (2003) Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes Infect 5(12):1057–1063. https://doi.org/10.1016/s1286-4579(03)00207-7CrossRefPubMed

115.

Devaraj S, Tobias P, Jialal I (2011) Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 55(3):441–445. https://doi.org/10.1016/j.cyto.2011.03.023CrossRefPubMed

116.

Bours V, Bonizzi G, Bentires-Alj M, Bureau F, Piette J, Lekeux P, Merville M (2000) NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology 153(1–3):27–38. https://doi.org/10.1016/s0300-483x(00)00302-4CrossRefPubMed

117.

Chen L, Chen R, Wang H, Liang F (2015) Mechanisms Linking Inflammation to Insulin Resistance. Int J Endocrinol 2015:508409. https://doi.org/10.1155/2015/508409CrossRefPubMedPubMedCentral

118.

Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL (2019) Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med 18(5):3461–3469. https://doi.org/10.3892/etm.2019.7943CrossRefPubMedPubMedCentral

119.

Cani PD, Delzenne NM (2011) The gut microbiome as therapeutic target. Pharmacol Ther 130(2):202–212. https://doi.org/10.1016/j.pharmthera.2011.01.012CrossRefPubMed

120.

Palau-Rodriguez M, Tulipani S, Isabel Queipo-Ortuno M, Urpi-Sarda M, Tinahones FJ, Andres-Lacueva C (2015) Metabolomic insights into the intricate gut microbial-host interaction in the development of obesity and type 2 diabetes. Front Microbiol 6:1151. https://doi.org/10.3389/fmicb.2015.01151CrossRefPubMedPubMedCentral

121.

Quevrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermudez-Humaran LG, Pigneur B, Lequin O, Kharrat P, Thomas G, Rainteau D, Aubry C, Breyner N, Afonso C, Lavielle S, Grill JP, Chassaing G, Chatel JM, Trugnan G, Xavier R, Langella P, Sokol H, Seksik P (2016) Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 65(3):415–425. https://doi.org/10.1136/gutjnl-2014-307649CrossRefPubMed

122.

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105(43):16731–16736. https://doi.org/10.1073/pnas.0804812105CrossRefPubMedPubMedCentral

123.

Breyner NM, Michon C, de Sousa CS, Vilas Boas PB, Chain F, Azevedo VA, Langella P, Chatel JM (2017) Microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii shows a protective effect on DNBS and DSS-induced colitis model in mice through inhibition of NF-kappaB pathway. Front Microbiol 8:114. https://doi.org/10.3389/fmicb.2017.00114CrossRefPubMedPubMedCentral

124.

Xu J, Liang R, Zhang W, Tian K, Li J, Chen X, Yu T, Chen Q (2020) Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes 12(3):224–236. https://doi.org/10.1111/1753-0407.12986CrossRefPubMed

125.

Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S (2018) The microbial metabolite indole-3-propionic acid improves glucose metabolism in rats, but does not affect behaviour. Arch Physiol Biochem 124(4):306–312. https://doi.org/10.1080/13813455.2017.1398262CrossRefPubMed

126.

Chimerel C, Emery E, Summers DK, Keyser U, Gribble FM, Reimann F (2014) Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep 9(4):1202–1208. https://doi.org/10.1016/j.celrep.2014.10.032CrossRefPubMedPubMedCentral

127.

de Mello VD, Paananen J, Lindstrom J, Lankinen MA, Shi L, Kuusisto J, Pihlajamaki J, Auriola S, Lehtonen M, Rolandsson O, Bergdahl IA, Nordin E, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Landberg R, Eriksson JG, Tuomilehto J, Hanhineva K, Uusitupa M (2017) Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the finnish diabetes prevention study. Sci Rep 7:46337. https://doi.org/10.1038/srep46337CrossRefPubMedPubMedCentral

128.

Karamanos B, Thanopoulou A, Angelico F, Assaad-Khalil S, Barbato A, Del Ben M, Dimitrijevic-Sreckovic V, Djordjevic P, Gallotti C, Katsilambros N, Migdalis I, Mrabet M, Petkova M, Roussi D, Tenconi MT (2002) Nutritional habits in the Mediterranean Basin. The macronutrient composition of diet and its relation with the traditional Mediterranean diet. Multi-centre study of the Mediterranean Group for the Study of Diabetes (MGSD). Eur J Clin Nutr 56(10):983–991. https://doi.org/10.1038/sj.ejcn.1601413CrossRefPubMed

129.

Aktas AB, Ozen B, Tokatli F, Sen I (2014) Phenolics profile of a naturally debittering olive in comparison to regular olive varieties. J Sci Food Agric 94(4):691–698. https://doi.org/10.1002/jsfa.6308CrossRefPubMed

130.

Lacatusu CM, Grigorescu ED, Floria M, Onofriescu A, Mihai BM (2019) The Mediterranean diet: from an environment-driven food culture to an emerging medical prescription. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16060942CrossRefPubMedPubMedCentral

131.

Sleiman D, Al-Badri MR, Azar ST (2015) Effect of mediterranean diet in diabetes control and cardiovascular risk modification: a systematic review. Front Public Health 3:69. https://doi.org/10.3389/fpubh.2015.00069CrossRefPubMedPubMedCentral

132.

Milanski M, Degasperi G, Coope A, Morari J, Denis R, Cintra DE, Tsukumo DM, Anhe G, Amaral ME, Takahashi HK, Curi R, Oliveira HC, Carvalheira JB, Bordin S, Saad MJ, Velloso LA (2009) Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 29(2):359–370. https://doi.org/10.1523/JNEUROSCI.2760-08.2009CrossRefPubMedPubMedCentral

133.

Casas R, Sacanella E, Estruch R (2014) The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases. Endocr Metab Immune Disord Drug Targets 14(4):245–254. https://doi.org/10.2174/1871530314666140922153350CrossRefPubMed

134.

Telle-Hansen VH, Gaundal L, Myhrstad MCW (2019) Polyunsaturated fatty acids and glycemic control in type 2 diabetes. Nutrients. https://doi.org/10.3390/nu11051067CrossRefPubMedPubMedCentral

135.

Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL, Azevedo MJ (2013) Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev 71(12):790–801. https://doi.org/10.1111/nure.12076CrossRefPubMed

136.

Bozzetto L, Costabile G, Della Pepa G, Ciciola P, Vetrani C, Vitale M, Rivellese AA, Annuzzi G (2018) Dietary fibre as a unifying remedy for the whole spectrum of obesity-associated cardiovascular risk. Nutrients. https://doi.org/10.3390/nu10070943CrossRefPubMedPubMedCentral

137.

Jardine M (2016) Nutrition considerations for microbiota health in diabetes. Diabetes Spectr 29(4):238–244. https://doi.org/10.2337/ds16-0003CrossRefPubMedPubMedCentral

138.

Salas-Salvado J, Diaz-Lopez A, Ruiz-Canela M, Basora J, Fito M, Corella D, Serra-Majem L, Warnberg J, Romaguera D, Estruch R, Vidal J, Martinez JA, Aros F, Vazquez C, Ros E, Vioque J, Lopez-Miranda J, Bueno-Cavanillas A, Tur JA, Tinahones FJ, Martin V, Lapetra J, Pinto X, Daimiel L, Delgado-Rodriguez M, Matia P, Gomez-Gracia E, Diez-Espino J, Babio N, Castaner O, Sorli JV, Fiol M, Zulet MA, Bullo M, Goday A, Martinez-Gonzalez MA, Investigators PR-P (2019) Effect of a lifestyle intervention program with energy-restricted mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus Trial. Diabetes Care 42(5):777–788. https://doi.org/10.2337/dc18-0836CrossRefPubMed

139.

Toobert DJ, Glasgow RE, Strycker LA, Barrera M Jr, Radcliffe JL, Wander RC, Bagdade JD (2003) Biologic and quality-of-life outcomes from the Mediterranean Lifestyle Program: a randomized clinical trial. Diabetes Care 26(8):2288–2293. https://doi.org/10.2337/diacare.26.8.2288CrossRefPubMed

140.

Itsiopoulos C, Brazionis L, Kaimakamis M, Cameron M, Best JD, O’Dea K, Rowley K (2011) Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study. Nutr Metab Cardiovasc Dis 21(9):740–747. https://doi.org/10.1016/j.numecd.2010.03.005CrossRefPubMed

141.

Elhayany A, Lustman A, Abel R, Attal-Singer J, Vinker S (2010) A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Diabetes Obes Metab 12(3):204–209. https://doi.org/10.1111/j.1463-1326.2009.01151.xCrossRefPubMed

142.

Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, Petrizzo M, Saccomanno F, Beneduce F, Ceriello A, Giugliano D (2009) Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med 151(5):306–314. https://doi.org/10.7326/0003-4819-151-5-200909010-00004CrossRefPubMed

143.

Garcia-Mantrana I, Selma-Royo M, Alcantara C, Collado MC (2018) Shifts on gut microbiota associated to mediterranean diet adherence and specific dietary intakes on general adult population. Front Microbiol 9:890. https://doi.org/10.3389/fmicb.2018.00890CrossRefPubMedPubMedCentral

144.

Gutierrez-Diaz I, Fernandez-Navarro T, Sanchez B, Margolles A, Gonzalez S (2016) Mediterranean diet and faecal microbiota: a transversal study. Food Funct 7(5):2347–2356. https://doi.org/10.1039/c6fo00105jCrossRefPubMed

145.

Haro C, Montes-Borrego M, Rangel-Zuniga OA, Alcala-Diaz JF, Gomez-Delgado F, Perez-Martinez P, Delgado-Lista J, Quintana-Navarro GM, Tinahones FJ, Landa BB, Lopez-Miranda J, Camargo A, Perez-Jimenez F (2016) Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J Clin Endocrinol Metab 101(1):233–242. https://doi.org/10.1210/jc.2015-3351CrossRefPubMed

146.

Balfego M, Canivell S, Hanzu FA, Sala-Vila A, Martinez-Medina M, Murillo S, Mur T, Ruano EG, Linares F, Porras N, Valladares S, Fontalba M, Roura E, Novials A, Hernandez C, Aranda G, Siso-Almirall A, Rojo-Martinez G, Simo R, Gomis R (2016) Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naive patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis 15:78. https://doi.org/10.1186/s12944-016-0245-0CrossRefPubMedPubMedCentral

147.

Meslier V, Laiola M, Roager HM, De Filippis F, Roume H, Quinquis B, Giacco R, Mennella I, Ferracane R, Pons N, Pasolli E, Rivellese A, Dragsted LO, Vitaglione P, Ehrlich SD, Ercolini D (2020) Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut 69(7):1258–1268. https://doi.org/10.1136/gutjnl-2019-320438CrossRefPubMed

148.

Kahleova H, Matoulek M, Malinska H, Oliyarnik O, Kazdova L, Neskudla T, Skoch A, Hajek M, Hill M, Kahle M, Pelikanova T (2011) Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with Type 2 diabetes. Diabet Med 28(5):549–559. https://doi.org/10.1111/j.1464-5491.2010.03209.xCrossRefPubMedPubMedCentral

149.

Clarys P, Deliens T, Huybrechts I, Deriemaeker P, Vanaelst B, De Keyzer W, Hebbelinck M, Mullie P (2014) Comparison of nutritional quality of the vegan, vegetarian, semi-vegetarian, pesco-vegetarian and omnivorous diet. Nutrients 6(3):1318–1332. https://doi.org/10.3390/nu6031318CrossRefPubMedPubMedCentral

150.

Kahleova H, Dort S, Holubkov R, Barnard ND (2018) A plant-based high-carbohydrate, low-fat diet in overweight individuals in a 16-week randomized clinical trial: the role of carbohydrates. Nutrients. https://doi.org/10.3390/nu10091302CrossRefPubMedPubMedCentral

151.

Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green A, Ferdowsian H (2009) A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. Am J Clin Nutr 89(5):1588S-1596S. https://doi.org/10.3945/ajcn.2009.26736HCrossRefPubMedPubMedCentral

152.

Jain A, Li XH, Chen WN (2018) Similarities and differences in gut microbiome composition correlate with dietary patterns of Indian and Chinese adults. AMB Express 8(1):104. https://doi.org/10.1186/s13568-018-0632-1CrossRefPubMedPubMedCentral

153.

De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107(33):14691–14696. https://doi.org/10.1073/pnas.1005963107CrossRefPubMedPubMedCentral

154.

Ruengsomwong S, La-Ongkham O, Jiang J, Wannissorn B, Nakayama J, Nitisinprasert S (2016) Microbial Community of healthy thai vegetarians and non-vegetarians, their core gut microbiota, and pathogen risk. J Microbiol Biotechnol 26(10):1723–1735. https://doi.org/10.4014/jmb.1603.03057CrossRefPubMed

155.

Jeffery IB, O’Toole PW (2013) Diet-microbiota interactions and their implications for healthy living. Nutrients 5(1):234–252. https://doi.org/10.3390/nu5010234CrossRefPubMedPubMedCentral

156.

Matijasic BB, Obermajer T, Lipoglavsek L, Grabnar I, Avgustin G, Rogelj I (2014) Association of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia. Eur J Nutr 53(4):1051–1064. https://doi.org/10.1007/s00394-013-0607-6CrossRefPubMed

157.

David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505(7484):559–563. https://doi.org/10.1038/nature12820CrossRefPubMed

158.

Kim MS, Hwang SS, Park EJ, Bae JW (2013) Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 5(5):765–775. https://doi.org/10.1111/1758-2229.12079CrossRefPubMed

159.

Brooks AW, Priya S, Blekhman R, Bordenstein SR (2018) Gut microbiota diversity across ethnicities in the United States. PLoS Biol 16(12):e2006842. https://doi.org/10.1371/journal.pbio.2006842CrossRefPubMedPubMedCentral

160.

Gibson G, Scott K, Rastall R, Tuohy K, Hotchkiss A, Dubert-Ferrandon A, Gareau MG, Murphy EF, Saulnier D, Loh G, Macfarlane S, Delzenne N, Ringel Y, Kozianowski G, Dickmann RS, Lenoir-Wijnkoop I, Walker C, Buddington R (2010) Dietary prebiotics: current status and new definition. Food Sci Technol Bull Funct Food 7:1–19CrossRef

161.

He M, Shi B (2017) Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci 7:54. https://doi.org/10.1186/s13578-017-0183-1CrossRefPubMedPubMedCentral

162.

Swanson KS, de Vos WM, Martens EC, Gilbert JA, Menon RS, Soto-Vaca A, Hautvast J, Meyer PD, Borewicz K, Vaughan EE, Slavin JL (2020) Effect of fructans, prebiotics and fibres on the human gut microbiome assessed by 16S rRNA-based approaches: a review. Benef Microbes 11(2):101–129. https://doi.org/10.3920/BM2019.0082CrossRefPubMed

163.

Holscher HD, Caporaso JG, Hooda S, Brulc JM, Fahey GC Jr, Swanson KS (2015) Fiber supplementation influences phylogenetic structure and functional capacity of the human intestinal microbiome: follow-up of a randomized controlled trial. Am J Clin Nutr 101(1):55–64. https://doi.org/10.3945/ajcn.114.092064CrossRefPubMed

164.

Cani PD, Joly E, Horsmans Y, Delzenne NM (2006) Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 60(5):567–572. https://doi.org/10.1038/sj.ejcn.1602350CrossRefPubMed

165.

Dehghan P, Gargari BP, Jafar-Abadi MA, Aliasgharzadeh A (2014) Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial. Int J Food Sci Nutr 65(1):117–123. https://doi.org/10.3109/09637486.2013.836738CrossRefPubMed

166.

Pourghassem Gargari B, Dehghan P, Aliasgharzadeh A, Asghari Jafar-Abadi M (2013) Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 37(2):140–148. https://doi.org/10.4093/dmj.2013.37.2.140CrossRefPubMedPubMedCentral

167.

Russo F, Riezzo G, Chiloiro M, De Michele G, Chimienti G, Marconi E, D’Attoma B, Linsalata M, Clemente C (2010) Metabolic effects of a diet with inulin-enriched pasta in healthy young volunteers. Curr Pharm Des 16(7):825–831. https://doi.org/10.2174/138161210790883570CrossRefPubMed

168.

Kellow NJ, Coughlan MT, Reid CM (2014) Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 111(7):1147–1161. https://doi.org/10.1017/S0007114513003607CrossRefPubMed

169.

Gomes AC, Bueno AA, de Souza RG, Mota JF (2014) Gut microbiota, probiotics and diabetes. Nutr J 13:60. https://doi.org/10.1186/1475-2891-13-60CrossRefPubMedPubMedCentral

170.

Vulevic J, Juric A, Tzortzis G, Gibson GR (2013) A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 143(3):324–331. https://doi.org/10.3945/jn.112.166132CrossRefPubMed

171.

Canfora EE, van der Beek CM, Hermes GDA, Goossens GH, Jocken JWE, Holst JJ, van Eijk HM, Venema K, Smidt H, Zoetendal EG, Dejong CHC, Lenaerts K, Blaak EE (2017) Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology 153(1):87-97e83. https://doi.org/10.1053/j.gastro.2017.03.051CrossRefPubMed

172.

Costabile A, Klinder A, Fava F, Napolitano A, Fogliano V, Leonard C, Gibson GR, Tuohy KM (2008) Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. Br J Nutr 99(1):110–120. https://doi.org/10.1017/S0007114507793923CrossRefPubMed

173.

Nicolucci AC, Hume MP, Martinez I, Mayengbam S, Walter J, Reimer RA (2017) Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology 153(3):711–722. https://doi.org/10.1053/j.gastro.2017.05.055CrossRefPubMed

174.

Chambers ES, Byrne CS, Morrison DJ, Murphy KG, Preston T, Tedford C, Garcia-Perez I, Fountana S, Serrano-Contreras JI, Holmes E, Reynolds CJ, Roberts JF, Boyton RJ, Altmann DM, McDonald JAK, Marchesi JR, Akbar AN, Riddell NE, Wallis GA, Frost GS (2019) Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut 68(8):1430–1438. https://doi.org/10.1136/gutjnl-2019-318424CrossRefPubMed

175.

Rebello CJ, Burton J, Heiman M, Greenway FL (2015) Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: a randomized controlled pilot trial. J Diabetes Complicat 29(8):1272–1276. https://doi.org/10.1016/j.jdiacomp.2015.08.023CrossRef

176.

Schutte S, Esser D, Hoevenaars FPM, Hooiveld G, Priebe MG, Vonk RJ, Wopereis S, Afman LA (2018) A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandioos study, a randomized trial in overweight subjects. Am J Clin Nutr 108(6):1264–1274. https://doi.org/10.1093/ajcn/nqy204CrossRefPubMed

177.

Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA (2019) Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr 58(4):1735–1745. https://doi.org/10.1007/s00394-018-1721-2CrossRefPubMed

178.

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11(8):506–514. https://doi.org/10.1038/nrgastro.2014.66CrossRefPubMed

179.

Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, Jafari P, Esmaillzadeh A, Asemi Z (2017) Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int 91(2):435–442. https://doi.org/10.1016/j.kint.2016.09.040CrossRefPubMed

180.

Tonucci LB, Olbrich Dos Santos KM, Licursi de Oliveira L, Rocha Ribeiro SM, Duarte Martino HS (2017) Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Clin Nutr 36(1):85–92. https://doi.org/10.1016/j.clnu.2015.11.011CrossRefPubMed

181.

Bjerg AT, Kristensen M, Ritz C, Stark KD, Holst JJ, Leser TD, Wellejus A, Astrup A (2015) Four weeks supplementation with Lactobacillus paracasei subsp. paracasei L. casei W8(R) shows modest effect on triacylglycerol in young healthy adults. Benef Microbes 6(1):29–39. https://doi.org/10.3920/BM2014.0058CrossRefPubMed

182.

Bjerg AT, Kristensen M, Ritz C, Holst JJ, Rasmussen C, Leser TD, Wellejus A, Astrup A (2014) Lactobacillus paracasei subsp paracasei L. casei W8 suppresses energy intake acutely. Appetite 82:111–118. https://doi.org/10.1016/j.appet.2014.07.016CrossRefPubMed

183.

Yao K, Zeng L, He Q, Wang W, Lei J, Zou X (2017) Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: a meta-analysis of 12 randomized controlled trials. Med Sci Monit 23:3044–3053. https://doi.org/10.12659/msm.902600CrossRefPubMedPubMedCentral

184.

Tao YW, Gu YL, Mao XQ, Zhang L, Pei YF (2020) Effects of probiotics on type II diabetes mellitus: a meta-analysis. J Transl Med 18(1):30. https://doi.org/10.1186/s12967-020-02213-2CrossRefPubMedPubMedCentral

185.

Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, van Hylckama Vlieg JE, Strissel K, Zhao L, Obin M, Shen J (2015) Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J 9(1):1–15. https://doi.org/10.1038/ismej.2014.99CrossRefPubMed

186.

Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY (2017) Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. Eur J Nutr 56(4):1535–1550. https://doi.org/10.1007/s00394-016-1199-8CrossRefPubMed

187.

Jones RB, Alderete TL, Martin AA, Geary BA, Hwang DH, Palmer SL, Goran MI (2018) Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial. Pediatr Obes 13(11):705–714. https://doi.org/10.1111/ijpo.12273CrossRefPubMedPubMedCentral

188.

Simon MC, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, Zivehe F, Hwang JH, Stehle P, Pacini G, Hartmann B, Holst JJ, MacKenzie C, Bindels LB, Martinez I, Walter J, Henrich B, Schloot NC, Roden M (2015) Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care 38(10):1827–1834. https://doi.org/10.2337/dc14-2690CrossRefPubMed

189.

Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, Kanno R, Tamura Y, Asahara T, Takahashi T, Nomoto K, Yamashiro Y, Watada H (2017) Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep 7(1):12115. https://doi.org/10.1038/s41598-017-12535-9CrossRefPubMedPubMedCentral

190.

Hsieh MC, Tsai WH, Jheng YP, Su SL, Wang SY, Lin CC, Chen YH, Chang WW (2018) The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial. Sci Rep 8(1):16791. https://doi.org/10.1038/s41598-018-35014-1CrossRefPubMedPubMedCentral

191.

Gobel RJ, Larsen N, Jakobsen M, Molgaard C, Michaelsen KF (2012) Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr 55(6):673–678. https://doi.org/10.1097/MPG.0b013e318263066cCrossRefPubMed

192.

Brahe LK, Le Chatelier E, Prifti E, Pons N, Kennedy S, Blaedel T, Hakansson J, Dalsgaard TK, Hansen T, Pedersen O, Astrup A, Ehrlich SD, Larsen LH (2015) Dietary modulation of the gut microbiota–a randomised controlled trial in obese postmenopausal women. Br J Nutr 114(3):406–417. https://doi.org/10.1017/S0007114515001786CrossRefPubMedPubMedCentral

193.

Pandey KR, Naik SR, Vakil BV (2015) Probiotics, prebiotics and synbiotics: a review. J Food Sci Technol 52(12):7577–7587. https://doi.org/10.1007/s13197-015-1921-1CrossRefPubMedPubMedCentral

194.

Soleimani A, Motamedzadeh A, Zarrati Mojarrad M, Bahmani F, Amirani E, Ostadmohammadi V, Tajabadi-Ebrahimi M, Asemi Z (2019) The effects of synbiotic supplementation on metabolic status in diabetic patients undergoing hemodialysis: a randomized, double-blinded. Placebo-Controlled Trial Probiotics Antimicrob Proteins 11(4):1248–1256. https://doi.org/10.1007/s12602-018-9499-3CrossRefPubMed

195.

Moroti C, Souza Magri LF, de Rezende CM, Cavallini DC, Sivieri K (2012) Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 11:29. https://doi.org/10.1186/1476-511X-11-29CrossRefPubMedPubMedCentral

196.

Ebrahimi ZS, Nasli-Esfahani E, Nadjarzade A, Mozaffari-Khosravi H (2017) Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial. J Diabetes Metab Disord 16:23. https://doi.org/10.1186/s40200-017-0304-8CrossRefPubMedPubMedCentral

197.

Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A (2014) Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 33(2):198–203. https://doi.org/10.1016/j.clnu.2013.05.015CrossRefPubMed

198.

Mahboobi S, Rahimi F, Jafarnejad S (2018) Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: a meta-analysis of randomized controlled trials. Adv Pharm Bull 8(4):565–574. https://doi.org/10.15171/apb.2018.065CrossRefPubMedPubMedCentral

199.

Angelino D, Martina A, Rosi A, Veronesi L, Antonini M, Mennella I, Vitaglione P, Grioni S, Brighenti F, Zavaroni I, Fares C, Torriani S, Pellegrini N (2019) Glucose- and lipid-related biomarkers are affected in healthy obese or hyperglycemic adults consuming a whole-grain pasta enriched in prebiotics and probiotics: a 12-week randomized controlled trial. J Nutr 149(10):1714–1723. https://doi.org/10.1093/jn/nxz071CrossRefPubMed

200.

Horvath A, Leber B, Feldbacher N, Tripolt N, Rainer F, Blesl A, Trieb M, Marsche G, Sourij H, Stadlbauer V (2020) Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Eur J Nutr 59(7):2969–2983. https://doi.org/10.1007/s00394-019-02135-wCrossRefPubMed

201.

Kim KO, Gluck M (2019) Fecal microbiota transplantation: an update on clinical practice. Clin Endosc 52(2):137–143. https://doi.org/10.5946/ce.2019.009CrossRefPubMedPubMedCentral

202.

Kootte RS, Levin E, Salojarvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, Knop FK, Blaak EE, Zhao J, Smidt H, Harms AC, Hankemeijer T, Bergman J, Romijn HA, Schaap FG, Olde Damink SWM, Ackermans MT, Dallinga-Thie GM, Zoetendal E, de Vos WM, Serlie MJ, Stroes ESG, Groen AK, Nieuwdorp M (2017) Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 26(4):611–619616. https://doi.org/10.1016/j.cmet.2017.09.008CrossRefPubMed

203.

Smits LP, Kootte RS, Levin E, Prodan A, Fuentes S, Zoetendal EG, Wang Z, Levison BS, Cleophas MCP, Kemper EM, Dallinga-Thie GM, Groen AK, Joosten LAB, Netea MG, Stroes ESG, de Vos WM, Hazen SL, Nieuwdorp M (2018) Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.008342CrossRefPubMedPubMedCentral

204.

Yu EW, Gao L, Stastka P, Cheney MC, Mahabamunuge J, Torres Soto M, Ford CB, Bryant JA, Henn MR, Hohmann EL (2020) Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med 17(3):e1003051. https://doi.org/10.1371/journal.pmed.1003051CrossRefPubMedPubMedCentral

205.

Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, McKenzie C, Summers K, Reid G, Burton JP, Silverman M (2020) Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol 115(7):1055–1065. https://doi.org/10.14309/ajg.0000000000000661CrossRefPubMed

206.

Whang A, Nagpal R, Yadav H (2019) Bi-directional drug-microbiome interactions of anti-diabetics. EBioMedicine 39:591–602. https://doi.org/10.1016/j.ebiom.2018.11.046CrossRefPubMed

Titel: Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes
verfasst von: Yasaman Ghorbani
Katherine J. P. Schwenger
Johane P. Allard
Publikationsdatum: 02.03.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 5/2021
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-021-02520-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier

Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis

A maternal high-fat/low-fiber diet impairs glucose tolerance and induces the formation of glycolytic muscle fibers in neonatal offspring

Acute supplementation with grapes in obese subjects did not affect postprandial metabolism: a randomized, double-blind, crossover clinical trial

Ten days of complete fasting affected subjective sensations but not cognitive abilities in healthy adults